Aimei Health Q2 Loss Widens, Cash Dwindles to $1,466 as SPAC Deadline Looms
AFJK sits 78% above its 52-week low of $6.75 on light trading volume (0.4× avg).
Summary
Aimei Health's Q2 2026 10-Q shows a net loss, near-zero operating cash, and a going-concern warning, with the SPAC's business combination deadline now just weeks away after the United Hydrogen deal collapsed.
Key Events · Earnings and Guidance · AFJK
-
Q2 Net Loss of $83,144
For the three months ended June 30, 2026, Aimei Health reported a net loss of $83,144, compared to net income of $424,970 in the same period last year. The loss was driven by $192,348 in general and administrative costs, only partially offset by $109,204 in trust interest income.
-
Operating Cash Down to $1,466
As of June 30, 2026, the company had just $1,466 in its operating bank account and a working capital deficit of $3,794,718. The trust account held $12,488,393, but those funds are restricted for shareholder redemptions or a business combination.
-
Going Concern Warning Reiterated
Management states that if the company cannot complete a business combination within the Combination Period (now December 6, 2026, subject to monthly extensions), it will cease operations, redeem public shares, and liquidate. This raises substantial doubt about the company's ability to continue as a going concern.
-
Material Weakness in Internal Controls
The company's disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness from inadequate segregation of duties and insufficient written policies and procedures for accounting, IT, and financial reporting.
Analysis · AFJK · Real Estate & Construction
Aimei Health reported a net loss of $83,144 for Q2 2026, reversing a $424,970 profit a year earlier, while operating cash fell to just $1,466. The company's working capital deficit stands at $3.79 million, and management again flags substantial doubt about its ability to continue as a going concern. With the United Hydrogen merger terminated in July and the business combination deadline extended only through September 6, 2026, the company has less than a month to find a new target or face liquidation. The filing also confirms a material weakness in internal controls, compounding the governance concerns already raised by Nasdaq delisting notices.
At the time of this filing, AFJK was trading at $11.99 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $38M. The 52-week trading range was $6.75 to $130.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.